NEW YORK – Single-cell proteomics firm IsoPlexis is looking to expand its market reach with the launch of a lower-priced, smaller-footprint platform and new assay capabilities.
The company also continues to move its technology into the clinic, having identified a blood-based biomarker of response to immunotherapy in melanoma that researchers presented on at the Society for Immunotherapy of Cancer (SITC) annual meeting this month.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
